Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations
Venessa Tsang, C. Roney
European Psychiatry April 1, 2024 DOI: 10.1192/j.eurpsy.2024.1252 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Case report Peer reviewed |
|---|---|
| Population | Patients on the waitlist of psilocybin-assisted therapy and their care providers |
| Intervention | Psilocybin-assisted therapy |
| Topics | Psilocybin |
| Keywords | Psychotherapist |
| Citations | 1 |
| Key findings | Barriers such as complex application processes, fear of judgement, logistical and financial constraints, and systemic inequities, along with Health Canada's stringent control, hinder equitable access to psilocybin-assisted therapy. |
Abstract
Introduction: Psilocybin-assisted therapy (PAT) has demonstrated significant potential in alleviating anxiety, depression, and psychological distress among individuals with terminal illnesses. However, numerous barriers prevent equitable access to this transformative treatment.
Objectives: This study seeks to gather the perspectives of patients on the waitlist of PAT.
Methods: Semi-structured interviews highlight the challenges faced by patients seeking PAT and their care providers and propose recommendations to enhance accessibility.
Results: Through a case study of Roots to Thrive, a non-profit healthcare practice offering group-based PAT, obstacles such as complex application processes, fear of judgement, logistical and financial constraints, and systemic inequities are revealed. Moreover, Health Canada’s stringent control of PAT access via clinical trials and the Special Access Program (SAP) presents challenges for primary care providers and hinders the involvement of trained practitioners. The moral distress experienced by patients and providers due to delayed or denied access further emphasizes the urgency of addressing these barriers.
Conclusions: Advocates are calling for streamlined referral systems, expedited services for end-of-life patients, formal billing infrastructure, practitioner education, expanded coverage, legislative adjustments, post-therapy support, and collaboration with non-profit organizations and Indigenous Healers to promote equitable and effective PAT. By implementing these recommendations, barriers to PAT can be overcome, allowing more individuals to benefit from this therapy and find relief from the psychological distress associated with their conditions. Disclosure of Interest None Declared
Comparable studies
Other qualitative studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression enrolled in an open-label trial of psilocybin | 2017 | Qualitative study | n = 20 |
| Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis Adults aged 22 to 69 with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study | n = 13 |
| Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts Participants who completed a psilocybin-facilitated smoking cessation pilot study | 2018 | Qualitative follow-up study using semi-structured interviews and thematic analysis | n = 12 |
| Response of cluster headache to psilocybin and LSD Cluster headache patients who used psilocybin or LSD | 2006 | Qualitative study | n = 53 |
| Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress Adult participants with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study using interpretative phenomenological analysis | n = 13 |